ATE520411T1 - Behandlung und prävention von lungenerkrankungen - Google Patents

Behandlung und prävention von lungenerkrankungen

Info

Publication number
ATE520411T1
ATE520411T1 AT03719918T AT03719918T ATE520411T1 AT E520411 T1 ATE520411 T1 AT E520411T1 AT 03719918 T AT03719918 T AT 03719918T AT 03719918 T AT03719918 T AT 03719918T AT E520411 T1 ATE520411 T1 AT E520411T1
Authority
AT
Austria
Prior art keywords
prevention
treatment
methods
compositions
lung diseases
Prior art date
Application number
AT03719918T
Other languages
German (de)
English (en)
Inventor
Charles G Cochrane
Zenaida G Oades
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of ATE520411T1 publication Critical patent/ATE520411T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03719918T 2002-04-25 2003-04-25 Behandlung und prävention von lungenerkrankungen ATE520411T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37596802P 2002-04-25 2002-04-25
PCT/US2003/012731 WO2003090682A2 (en) 2002-04-25 2003-04-25 Treatment and prevention of pulmonary conditions

Publications (1)

Publication Number Publication Date
ATE520411T1 true ATE520411T1 (de) 2011-09-15

Family

ID=29270737

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03719918T ATE520411T1 (de) 2002-04-25 2003-04-25 Behandlung und prävention von lungenerkrankungen

Country Status (13)

Country Link
US (2) US7863241B2 (https=)
EP (1) EP1558273B1 (https=)
JP (2) JP4651946B2 (https=)
KR (2) KR101036058B1 (https=)
CN (1) CN1838964A (https=)
AT (1) ATE520411T1 (https=)
AU (1) AU2003223718B2 (https=)
CA (1) CA2483102C (https=)
IL (2) IL164795A0 (https=)
MX (1) MXPA04010560A (https=)
NZ (1) NZ536796A (https=)
WO (1) WO2003090682A2 (https=)
ZA (1) ZA200408573B (https=)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003223718B2 (en) 2002-04-25 2007-08-16 The Scripps Research Institute Treatment and prevention of pulmonary conditions
EP1694314A4 (en) * 2003-12-04 2009-07-01 Scripps Research Inst TREATMENT AND PREVENTION OF ASTHMA
WO2005073246A2 (en) * 2004-01-20 2005-08-11 Discovery Laboratories, Inc. Method for preparing kl4 lung surfactant
WO2005087249A1 (ja) * 2004-03-11 2005-09-22 Kurume University プロテアーゼ阻害剤及び疾患の予防又は治療剤
US7678767B2 (en) 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
US7553810B2 (en) 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
US7608579B2 (en) 2004-06-16 2009-10-27 Pneumrx, Inc. Lung volume reduction using glue compositions
US7468350B2 (en) 2004-06-16 2008-12-23 Pneumrx, Inc. Glue composition for lung volume reduction
CA2570261C (en) 2004-07-08 2014-06-10 Pneumrx, Inc. Pleural effusion treatment device, method and material
EP1791555B1 (en) * 2004-09-10 2013-03-13 Pharmaorigin ApS Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis
US8337815B2 (en) * 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
WO2006071102A1 (en) * 2004-12-30 2006-07-06 Dobeel Co., Ltd. Spray-dried composition containing collectin family proteins or variants therof and process for preparing the same
GB0510463D0 (en) * 2005-05-23 2005-06-29 Britania Pharmaceuticals Ltd Improvements in or relating to organic materials
WO2006136962A2 (en) * 2005-06-24 2006-12-28 Drugrecure Aps Airway administration of tissue factor pathway inhibitor in inflammatory conditons affecting the respiratory tract
WO2007005672A2 (en) * 2005-06-30 2007-01-11 The Scripps Research Institute Treatment and prevention of respiratory diseases and conditions
WO2008121811A2 (en) * 2007-03-29 2008-10-09 National Jewish Medical And Research Center Surfactant lipids, compositions thereof, and uses thereof
EP1997502A1 (en) * 2007-06-01 2008-12-03 CHIESI FARMACEUTICI S.p.A. Reconstituted surfactants having improved properties
AU2008259768B2 (en) * 2007-06-05 2013-08-29 Paka Pulmonary Pharmaceuticals, Inc. Compositions for delivering medicaments into the lungs, uses thereof
US20110142914A1 (en) * 2007-12-06 2011-06-16 Cytotech Labs, Llc Inhalable compositions having enhanced bioavailability
GB0724772D0 (en) * 2007-12-19 2008-01-30 Ucl Business Plc Carrier
WO2010068754A2 (en) * 2008-12-10 2010-06-17 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of medicaments to the lungs
EP2391379B1 (en) 2009-01-30 2017-08-02 Alphabeta AB Compound and method for treatment of alzheimer's disease
US8434479B2 (en) * 2009-02-27 2013-05-07 Covidien Lp Flow rate compensation for transient thermal response of hot-wire anemometers
JP5622728B2 (ja) * 2009-08-06 2014-11-12 一般財団法人化学及血清療法研究所 咳嗽抑制効果を持つ血漿タンパク質
DK2308489T3 (da) * 2009-10-05 2014-03-24 Nutri Fit Gmbh & Co Kg Sammensætninger til anvendelse ved behandling eller forebyggelse af lungeskade, der fremkaldes af en stofskiftebelastning samt fremgangsmåder til forøgelse af pattedyrs fysiske kapacitet
AU2010315325B2 (en) 2009-11-03 2014-11-27 Grifols Therapeutics Inc. Composition, method, and kit for alpha-1 proteinase inhibitor
PT2503995T (pt) 2009-11-24 2017-11-23 Grifols Therapeutics Inc Métodos de liofilização, composições e kits
GB201003559D0 (en) * 2010-03-03 2010-04-21 Proteo Biotech Ag Novel use of elafin
SG10202010355PA (en) 2010-03-12 2020-11-27 Berg Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
AU2010356144B2 (en) 2010-06-24 2015-06-04 Alphabeta Ab Compound and method for treatment of Alzheimer's disease and familial dementia
CN101897720B (zh) * 2010-07-27 2015-09-09 北京华禧联合科技发展有限公司 一种治疗呼吸道疾病的药物组合物
EP2637681A4 (en) * 2010-11-04 2015-09-23 Univ Oklahoma PEPTIDE COMPOSITIONS FOR DOWN-REGULATING THE TLR-4 SIGNAL PATH AND METHOD FOR THE PRODUCTION AND USE THEREOF
US20130184202A1 (en) * 2011-02-08 2013-07-18 Changjiang Guo Peptide Inhibitors and Methods of Use Thereof
WO2012138284A1 (en) 2011-04-05 2012-10-11 Alphabeta Ab Amyloidosis target useful in methods of treatment and for screening of compounds
BR112013026313A8 (pt) * 2011-04-12 2018-01-30 Moerae Matrix Inc composições e métodos para prevenir ou tratar doenças, condições ou processos caracterizados por proliferação anormal de fibroblastos e depósito de matriz extracelular
US9890200B2 (en) 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
EP2720680B1 (en) 2011-06-17 2020-02-12 Berg LLC Inhalable pharmaceutical compositions
US9089657B2 (en) 2011-10-31 2015-07-28 Covidien Lp Methods and systems for gating user initiated increases in oxygen concentration during ventilation
WO2013188016A2 (en) * 2012-05-04 2013-12-19 Discovery Laboratories, Inc. Surfactant therapy for exposure to ionizing radiation
JP2016532456A (ja) 2013-09-18 2016-10-20 ジェームス・クック・ユニバーシティー 改変型抗炎症性タンパク質及び使用方法
CN105764523A (zh) * 2013-09-18 2016-07-13 詹姆斯库克大学 抗炎蛋白及使用方法
WO2015061412A1 (en) * 2013-10-22 2015-04-30 The Scripps Research Institute Methods and compositions for promoting bronchioli dilatation
US20180221462A1 (en) * 2014-08-26 2018-08-09 Proteo Biotech Ag Use of elafin for disorders associated with elastase independent increase in troponin
EP3300474A4 (en) 2015-04-27 2019-01-30 OmniActive Health Technologies Limited BETTUBO TOXIN COMPOSITIONS, METHOD FOR THE PRODUCTION THEREOF AND USES THEREOF
US10239847B1 (en) 2016-03-03 2019-03-26 Cellactin Method for 2-oxothiazolidine-4-carboxylic acid for cellular glutathione
CN109789193A (zh) * 2016-09-13 2019-05-21 普罗瑟拉生物公司 使用间α抑制蛋白治疗肺病的方法
CN110461351B (zh) * 2017-03-31 2024-03-26 艾娜呼吸私人有限公司 用tlr2激动剂治疗呼吸道感染
CA3085944A1 (en) * 2017-12-21 2019-06-27 Civitas Therapeutics, Inc. Surfactant formulations for inhalation
CN112654344A (zh) * 2018-04-17 2021-04-13 板层小体生物医学有限公司 抗纤维化组合物
CA3109798A1 (en) * 2018-08-17 2020-02-20 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of acute lung injury
BR112021007285A2 (pt) * 2018-10-19 2021-07-27 Ohio State Innovation Foundation nanocarreadores para terapia de inflamação pulmonar
CA3117213A1 (en) * 2018-10-23 2020-04-30 George Edward Hoag Composition and method for treating the lungs
CA3116015A1 (en) * 2018-10-30 2020-05-07 University Of Florida Research Foundation, Incorporated Amino acid compositions and methods for treating cystic fibrosis
CA3145702A1 (en) * 2019-08-01 2021-02-04 Philip A. Pemberton Oxidation-resistant serpins
KR102276935B1 (ko) * 2020-02-06 2021-07-12 한양대학교 산학협력단 신규한 비올라크산틴 고생산 클로렐라 불가리스 균주 및 이로부터 비올라크산틴을 생산하는 방법
EP4132470A4 (en) * 2020-04-08 2023-11-08 Arizona Board of Regents on behalf of the University of Arizona COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF LUNG DISEASES
WO2024097169A1 (en) * 2022-11-01 2024-05-10 National Jewish Health Treatment of coronavirus infections with antimicrobial phospholipid compositions
CN116421704A (zh) * 2023-02-20 2023-07-14 成都佩德生物医药有限公司 多肽pd-dp-005在制备治疗肺部疾病药物中的应用及其药物
CN120000688B (zh) * 2025-04-16 2025-08-05 山东杰凯生物科技有限公司 基于干细胞外囊泡的雾化吸入组合物及其制备方法、应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57144224A (en) * 1981-03-02 1982-09-06 Mochida Pharmaceut Co Ltd Remedy for respiratory dieseases
US4916117A (en) * 1986-12-24 1990-04-10 John Lezdey Treatment of inflammation using alpha 1-antichymotrypsin
US6013619A (en) * 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
US5260273A (en) * 1988-01-06 1993-11-09 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US5164369A (en) * 1988-01-06 1992-11-17 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5707634A (en) * 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
NO177716C (no) * 1989-06-09 1995-11-08 Zeneca Ltd Fremgangsmåte for fremstilling av terapeutisk aktive polypeptider, DNA-sekvens, ekspresjonsvektor og antistoff
AU638474B2 (en) * 1989-07-11 1993-07-01 Genentech Inc. Surfactant compositions and methods
US5993805A (en) * 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
US5272252A (en) * 1991-11-04 1993-12-21 Merrell Dow Pharmaceuticals Inc. Synthetic lung surfactant having antioxidant properties
AU664112B2 (en) * 1992-07-31 1995-11-02 Merrell Dow Pharmaceuticals Inc. Synthetic peptide lung surfactants having covalently bonded antioxidants
US5734014A (en) * 1992-08-11 1998-03-31 Tsumura & Co. Elafin derivative
AU5171293A (en) * 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
US5301644A (en) * 1993-06-16 1994-04-12 Kohler Co. Fuel shut-off mechanism for internal combustion engines
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
NZ284766A (en) * 1994-06-02 1998-06-26 Merrell Pharma Inc Perfluoro amino ketones; medicaments as elastase inhibitors
GB9413202D0 (en) * 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
US5878912A (en) * 1995-12-26 1999-03-09 Stein; Myron Duct disinfecting method and apparatus
US5874029A (en) * 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US5833891A (en) * 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5780440A (en) * 1996-06-17 1998-07-14 Protease Sciences Inc. Treatment of pulmonary disease with protease inhibitors
AU5719798A (en) * 1996-12-31 1998-07-31 Inhale Therapeutic Systems, Inc. Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
US6051257A (en) * 1997-02-24 2000-04-18 Superior Micropowders, Llc Powder batch of pharmaceutically-active particles and methods for making same
JPH11147832A (ja) * 1997-11-18 1999-06-02 Noevir Co Ltd 好中球エラスターゼ阻害剤
JP3796340B2 (ja) * 1997-11-18 2006-07-12 株式会社ノエビア セリンプロテアーゼ阻害剤
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US5883084A (en) * 1998-06-08 1999-03-16 Clarion Pharmaceuticals Inc. Treatment of respiratory diseases utilizing α-tocopheryl-phosphocholine
US6223455B1 (en) * 1999-05-03 2001-05-01 Acusphere, Inc. Spray drying apparatus and methods of use
US7053176B1 (en) * 1999-09-16 2006-05-30 Altana Pharma Ag Combination of C1-INH and lung surfactant for the treatment of respiratory disorders
IL150485A0 (en) * 1999-12-28 2002-12-01 Novartis Ag Method of achieving persistent transgene expression
EP1251868A1 (en) * 2000-01-06 2002-10-30 Eli Lilly & Company Combination therapy for the treatment of inflammatory and respiratory diseases
AU2003223718B2 (en) 2002-04-25 2007-08-16 The Scripps Research Institute Treatment and prevention of pulmonary conditions
US6819898B2 (en) * 2002-11-22 2004-11-16 Kabushiki Kaisha Toshiba Image forming apparatus including stopping member and backstop member to stop rotation of revolver type developing unit

Also Published As

Publication number Publication date
US20050070477A1 (en) 2005-03-31
CN1838964A (zh) 2006-09-27
KR20110017465A (ko) 2011-02-21
IL164795A (en) 2011-02-28
US20120189602A1 (en) 2012-07-26
EP1558273B1 (en) 2011-08-17
AU2003223718B2 (en) 2007-08-16
US7863241B2 (en) 2011-01-04
AU2003223718A1 (en) 2003-11-10
EP1558273A2 (en) 2005-08-03
EP1558273A4 (en) 2008-07-16
NZ536796A (en) 2007-03-30
WO2003090682A2 (en) 2003-11-06
JP2005529885A (ja) 2005-10-06
WO2003090682A3 (en) 2004-09-16
IL164795A0 (en) 2005-12-18
AU2003223718C1 (en) 2003-11-10
CA2483102A1 (en) 2003-11-06
ZA200408573B (en) 2006-03-29
CA2483102C (en) 2013-06-18
JP2011001383A (ja) 2011-01-06
KR20050019073A (ko) 2005-02-28
JP4651946B2 (ja) 2011-03-16
KR101036058B1 (ko) 2011-05-19
MXPA04010560A (es) 2005-08-15

Similar Documents

Publication Publication Date Title
ATE520411T1 (de) Behandlung und prävention von lungenerkrankungen
ATE451369T1 (de) Piperidinopyrimidindipeptidylpeptidaseinhibitor n zur behandlung von diabetes
ATE416761T1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
ATE448775T1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
ATE395083T1 (de) Verfahren zur behandlung von multipler sklerose durch hemmung der il-17-aktivität
NO20034056D0 (no) Proliferative sykdommer
ATE354563T1 (de) Sulfonderivate zur hemmung von gamma-secretase
MEP90508A (en) New pharmaceutical composition
ATE304350T1 (de) Probucol monoester zur behandlung von kreislauf- und entzündungserkrankungen
EA200401471A1 (ru) Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов
PT1509232E (pt) Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer
DE60310991D1 (de) Phenylalaninderivate als hemmer der dipeptidyl peptidase zur behandlung oder prävention von diabetes
DOP2002000525A (es) Inhibidores del factor xa y de otras proteasas de serina implicadas en la cascada de la coagulacion.
DK1163208T3 (da) Caspaseinhibitorer og anvendelser deraf
TR200002940T2 (tr) Parazitlerin sebep olduğu hastalıkların papain süperfamilyasından sistein proteazların inhibisyonu yoluyla tedavisi
DK0871454T3 (da) Phosphorholdige inhibitorer af cystein- og serinprotease
DE60026279D1 (de) Zusammenstellungen zur prophylaxe und behandlung von allergien des typus i
EP1032393A4 (en) QUINOLIN-CONTAINING ALPHA-KETOAMIDE-BASED INHIBITORS OF CYSTEIN AND SERINE PROTEASE
DE60220385D1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
ATE443044T1 (de) Tace inhibitoren
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE428425T1 (de) Spla2-inhibitoren zur behandlung von arteriosklerose
WO2004060878A3 (en) Inhibitors of phosphatases
CY1105166T1 (el) Ενωσεις φωσφονικου οξεος σαν αναστολεις πρωτεασων σepινης
DE50110552D1 (de) Verfahren zur behandlung von instabiler angina pectoris

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties